Sangamo Therapeutics (SGMOQ) Retained Earnings (2010 - 2025)

Sangamo Therapeutics has reported Retained Earnings for 16 years, with the latest figure at -$1.6 billion in Q4 2025.

• On a quarterly basis, Retained Earnings fell 8.17% year-over-year to -$1.6 billion in Q4 2025; TTM through Dec 2025 was -$1.6 billion, a 8.17% decrease from a year earlier, with the FY2025 full-year figure at -$1.6 billion, down 8.17% from the prior year.
• Retained Earnings was -$1.6 billion for Q4 2025 at Sangamo Therapeutics, down from -$1.6 billion in the prior quarter.
• The five-year high for Retained Earnings was -$823.9 million in Q1 2021, with the low at -$1.6 billion in Q4 2025.
• Average Retained Earnings over 5 years is -$1.3 billion, with a median of -$1.3 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings declined 29.1% in 2024, then dropped 4.24% in 2025.
• Over 5 years, Retained Earnings stood at -$956.3 million in 2021, then slipped by 20.1% to -$1.1 billion in 2022, then retreated by 22.45% to -$1.4 billion in 2023, then slipped by 6.96% to -$1.5 billion in 2024, then slipped by 8.17% to -$1.6 billion in 2025.
• The last three Retained Earnings figures came in at -$1.6 billion (Q4 2025), -$1.6 billion (Q3 2025), and -$1.6 billion (Q2 2025), per Business Quant data.